On this week's episode of Biotech Banter, senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss the tweet of the week from David Miller of AlpineBioVentures, who says, "Tip for those new to the ASCO thing: Abstracts are less than half the story. Posters & presentations are the real data."
We got a lot of data in the abstracts that were released earlier this month. But as David points, out there's more data to come.
The late-0breaking abstracts won't be released until the meeting begins on Friday. There investors can expect to see phase 2 data on AstraZeneca's (AZN 0.39%) ovarian cancer drug olaparib, phase 3 lung cancer data for Eli Lilly's (LLY 0.54%) Cyramza, and phase 3 data for Johnson & Johnson (JNJ 0.22%) and Pharmacyclics' Imbruvica in elderly patients with CLL. There will also be a couple of high-profile melanoma studies: Bristol-Myers Squibb's (BMY -0.87%) Yervoy as an adjuvant therapy after surgery and the use of Merck's (MRK 0.25%) MK-3475 in patients who haven't received Yervoy.
Investors can also look forward to expanded data from the abstracts that were released last week. Brian highlights safety data for Bristol-Myers Squibb's Yervoy-PD1 combo that he's looking forward to seeing. Watch the following video for further insight on what to expect at ASCO.
